The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAlliance Pharma Regulatory News (APH)

Share Price Information for Alliance Pharma (APH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 34.95
Bid: 34.65
Ask: 34.70
Change: 3.35 (10.60%)
Spread: 0.05 (0.144%)
Open: 31.00
High: 35.10
Low: 31.00
Prev. Close: 31.60
APH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appointment of Non-Executive Directors

7 Nov 2023 07:00

RNS Number : 5585S
Alliance Pharma PLC
07 November 2023
 

For immediate release

7 November 2023

 

 

ALLIANCE PHARMA

("Alliance", "Company" or the "Group")

 

Appointment of Non-Executive Directors

 

Alliance Pharma plc (AIM: APH), the international healthcare group, is pleased to announce the appointment of Eva-Lotta Sjöstedt and Richard McKenzie as new independent Non-Executive Directors to strengthen the Board and support the delivery of the Company's growth strategy. Both Eva-Lotta and Richard will join the Board with immediate effect.

 

Eva-Lotta Sjöstedt

Eva-Lotta has in-depth knowledge of global consumer retail, supply chain and digital transformation and has held leadership roles in consumer-facing industries across Europe, Japan, China and the USA.

 

From 2016 to 2018, Eva-Lotta was CEO of Georg Jensen, the luxury jewellery and Scandinavian design brand, where she led a global team of 1,400 to implement an omni-channel turnaround in retail networks. Prior to this Eva-Lotta was CEO at Karstadt, a chain of premium department stores in Germany with a strong e-commerce presence. She started her career at IKEA, establishing the business in Japan where she worked for four years before becoming CEO of IKEA Netherlands and then Deputy Global Retail Manager. In this role she was responsible for IKEA's global multi-channel strategy and the implementation of its on and offline experiences throughout the entire global value chain.

 

Eva-Lotta is currently a NED at FTSE-250 listed Tritax Eurobox, which operates, manages and invests in real estate assets across Continental Europe. Eva-Lotta joined the Board of Tritax Eurobox in 2019 and she Chairs the ESG committee and sits on the Nomination and Management Engagement committees. She is a member of the Board of ELISA Oyj, a digital services and telecommunications company listed on Nasdaq Helsinki, and is also a member of the Supervisory Board of Metro AG, a German wholesale food specialist operating in 35 countries.

 

We believe that Eva-Lotta's experience will strengthen the European dimension of the Alliance Board whilst providing valuable e-commerce and multi-channel experience.

 

Richard McKenzie

Richard has international e-commerce, distribution, supply chain and logistics experience in the consumer, retail and technology sectors, along with particular expertise in the Asia-Pacific region having lived and worked in mainland China for 10 years.

 

From 2019 to 2023, Richard was Chief Commercial Officer and latterly President (Europe and Asia) for Ocado Solutions, driving the growth of this leading grocery e-commerce platform globally. During his tenure at Ocado Solutions, Richard led major new deals with distributors in Korea, Japan, Spain and Poland, and redesigned the B2B organisation of the business. Prior to this Richard was a strategy consultant for OC&C in London and China, building the company's presence in Asia-Pacific, before becoming a Senior Partner for the Consumer Goods and Retail practice of Oliver Wyman in Asia Pacific. During this time, he built extensive experience of the retail consumer market in China, and Asia-Pacific more broadly.

 

Richard is currently a Senior Advisor to McKinsey and Company.

 

We believe that Alliance will benefit from Richard's significant operational experience, particularly in the rapidly evolving distribution channels and cross border e-commerce markets in China and Asia-Pacific, whilst his career in consultancy will bring additional strategic oversight.

 

Jo LeCouilliard, Chair of Alliance, said:

"I am delighted to welcome Eva-Lotta and Richard to the Board and look forward to their contribution to support the delivery of our growth strategy. Eva-Lotta will bring significant additional global consumer expertise from her various senior executive leadership roles, and Richard will bring significant additional strategic and operational expertise, particularly in our important China market."

 

The following information is disclosed pursuant to Schedule Two, paragraph (g), of the AIM Rules for Companies.

 

Mrs Eva-Lotta Saga Sjöstedt, aged 56, has been a director of the following companies during the five years preceding the date of this announcement:

 

Current directorships

? Metro AG

? Tritax Eurobox PLC

? Elisa Oyj

? Pigos Holding AB

? Tultan AB

? Kuno Leadership Community AB

 

Directorships in the past five years:

 

None within past five years

 

Mrs Eva-Lotta Sjöstedt does not hold any ordinary shares of 1 pence each in the Company.

 

 

Mr Richard Alexander McKenzie, aged 51, has been a director of the following companies during the five years preceding the date of this announcement:

 

Current directorships

? Strategy Max Ltd

? Karakuri Ltd*

? Ocado Intelligent Automation Ltd

Directorships in the past five years:

 

None within past five years

 

 

* Karakuri Ltd was placed into administration by its directors on 28 July 2023. All substantive trade and employee liabilities were settled in full, and shareholder loan notes were written off.

 

Mr Richard McKenzie does not hold any ordinary shares of 1 pence each in the Company.

 

 

For further information:

 

Alliance Pharma plc

+ 44 (0)1249 466966

Cora McCallum, Head of Investor Relations & Corporate Communications

+ 44 (0)1249 705168

ir@allianceph.com

 

 

 

Buchanan

+ 44 (0)20 7466 5000

Mark Court / Sophie Wills

 

alliancepharma@buchanan.uk.com

 

 

 

Deutsche Numis (Nominated Adviser and Joint Broker)

+ 44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Sher Shah

 

 

Investec Bank plc (Joint Broker)

+ 44 (0)20 7597 5970

Corporate Broking: Patrick Robb / Maria Gomez de Olea

 

 

 

About Alliance

 

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our purpose is to improve the lives of consumers and patients through making available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented by a smaller Prescription Medicines business. In total, we hold marketing rights to around 80 brands, with revenues generated from a mix of direct, distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics operations, we remain asset-light and focused on maximising the value of our brands.

For more information on Alliance, please visit our websitewww.alliancepharmaceuticals.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAGZMGMLVNGFZM
Date   Source Headline
31st Dec 20187:00 amRNSBlock Listing Six Monthly Return
17th Dec 20187:00 amRNSAppointment of Non-Executive Directors
6th Dec 20187:00 amRNSTotal Voting Rights
12th Nov 20183:51 pmRNSDirector Share Dealing
7th Nov 20181:35 pmEQSHardman & Co Research: Alliance Pharma (APH): International brands driving performance
5th Oct 201810:25 amRNSGrant of Options to Directors
2nd Oct 20187:00 amRNSXonvea launch in the UK
19th Sep 20187:00 amRNSInterim results
16th Aug 20187:00 amRNSNotice of Results
10th Aug 201810:00 amRNSTotal Voting Rights
1st Aug 20189:56 amEQSHardman & Co Research: Alliance Pharma (APH): 2018: a year of international progress
25th Jul 20187:00 amRNSHalf Year Trading Update
6th Jul 20187:00 amRNSMarketing Authorisation for Diclectin
29th Jun 20187:00 amRNSBlock Listing Six Monthly Return
25th Jun 20189:39 amRNSNotification of Major Holdings
22nd Jun 201811:58 amRNSNotification of Major Holdings
21st Jun 20184:13 pmRNSCompletion of Acquisition and TVR
19th Jun 20182:24 pmRNSResult of Placing
19th Jun 20187:00 amRNSNizoral Acquisition in APAC and Proposed Placing
18th Jun 20185:19 pmRNSNotification of Major Holdings
18th Jun 20185:17 pmRNSNotification of Major Holdings
7th Jun 20187:00 amRNSPositive Opinion on Diclectin
5th Jun 20181:03 pmRNSTotal Voting Rights
30th May 20187:00 amRNSDirectorate Change
24th May 20184:05 pmRNSNotification of Major Holdings
24th May 201811:00 amRNSResult of AGM
24th May 20187:00 amRNSAGM Statement
16th May 20183:05 pmRNSNotification of Major Holdings
2nd May 201812:32 pmRNSTotal Voting Rights
19th Apr 20185:25 pmRNSAnnual Report and AGM Notice
19th Apr 20184:59 pmRNSNotification of Major Holdings
19th Apr 20187:17 amEQSHardman & Co Research: Alliance Pharma (APH): Entering the US market
17th Apr 20187:00 amRNSDisposal of Chinese rights to Forceval
13th Apr 20187:00 amRNSAlliance to present at the UK Investor Show
3rd Apr 20184:09 pmRNSTotal Voting Rights
27th Mar 20187:00 amRNSFull Year Results
6th Mar 20181:48 pmRNSTotal Voting Rights
1st Mar 20187:00 amRNSDirectorate Changes
8th Feb 20185:49 pmRNSTotal Voting Rights
8th Feb 20185:47 pmRNSNotification of Major Holdings
8th Feb 20187:00 amRNSNotification of Preliminary Results
29th Jan 201811:20 amRNSHardman Research: Strong Operational Cashflow
22nd Jan 20187:00 amRNSPre-Close Trading Update
11th Jan 20187:15 amRNSHardman Research: Acquisitions to boost growth
2nd Jan 20182:00 pmRNSTotal Voting Rights
2nd Jan 20187:00 amRNSBlock Listing Six Monthly Return
28th Dec 20177:00 amRNSCompletion of acquisition of Vamousse
22nd Dec 20177:00 amRNSBlock Listing Six Monthly Return
4th Dec 20177:00 amRNSProposed acquisition of Vamousse
4th Dec 20177:00 amRNSTender Offer to Shareholders and Notice of Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.